Evidence map›Paper›PMID 40831640›Full record

ArticleFrontiers in microbiology2025

Unique genetic signatures in HIV-1 subtype A1 and A1D recombinant envelope glycoprotein distinguish contemporary transmitted/founder viruses from historical strains in East Africa.

Frank Kato, Anne Kapaata, Ronald Galiwango, Angella Nakyanzi, Christian Ndekezi, Fortunate Natwijuka, Denis Omara, Andrew Ekii Obuku, Brian Foley, Pontiano Kaleebu and 2 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Frank Kato *MRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Anne Kapaata *MRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Ronald GaliwangoThe African Centre of Excellence in Bioinformatics and Data Intensive Sciences, Kampala, Uganda.
Angella NakyanziUganda Virus Research Institute, Entebbe, Uganda.
Christian NdekeziMRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Fortunate NatwijukaMRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Denis OmaraMRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Andrew Ekii ObukuMRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Brian FoleyTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Pontiano KaleebuMRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.
Eunice NduatiKEMRI Wellcome Trust Research Programme, Kilifi, Kenya.
Sheila Nina BalindaMRC/UVRI & LSHTM Uganda Research Unit, Department of Viral Pathogens, Entebbe, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The envelope glycoprotein (Env) of HIV-1 Transmitted/Founder (T/F) viruses in subtypes B and C carries distinct genetic signatures that enhance transmission fitness, augment infectivity and immune evasion. However, there is limited data on such signatures in T/F subtypes A1, D and A1D recombinants that predominate East Africa's HIV epidemic. Methods: We used phylogenetically corrected approaches to detect distinct genetic signatures by comparing 44 contemporary HIV-1 T/F Envs with 229 historical Envs of the same subtype in East Africa. Results and Discussion: Subtype analysis based on the full-length Env gene of contemporary T/F viruses revealed a high proportion of subtype A1, followed by A1D recombinants, and fewer subtype D. Signature analysis revealed that the contemporary subtype A1 T/Fs were more likely to select distinct amino acids, including M22 in the signal peptide, R82 in gp120, A172 in the V2 loop, E230 in the glycosite 230, K275 in the D loop, Y317 in the V3 loop, K476 and N477 in the CD4 contact site, when compared with the historical Envs (q-value < 0.2). Conversely, the contemporary subtype A1 T/F Envs were less likely to carry the amino acids Q432 in the CD4 contact site, and the L784 signature within the LLP-2 (q-value < 0.2). The A1D recombinant T/Fs were more likely to select the D620 in the C-helix, but under selected the L34 in gp120, P299 in the V3 loop and Y643 in the Heptad repeat-2, compared to the historical Envs (q-value < 0.2). The distinct signature sites reported in this study may contribute to the successful establishment of acute infection as well as the persistence of long-term infection. Therefore, effective therapeutics and vaccines may target these distinct amino acid signatures especially for the East African region as it may be necessary to employ subtype-specific vaccines according to the subtype distribution.

Indexed as

A1D recombinantsenvelopegeneticHIV-1signaturesubtype A1transmitted/founder

Identifiers

PMID40831640
PMCPMC12358483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.